1. Generics Bulletin
  2. >>Products
  3. >>Generics

Generics Industry Preps For Potential Entry Of Ukraine Into EU

Generics Industry Has Provided Substantial Support Since Russian Invasion

 
• By Chloe Kent

Generics industry trade group Medicines for Europe has met with Ukrainian government officials to discuss how to plan for any future integration process.

EU and Ukraine flags
Ukraine has a long way to go before it potentially joins the EU, but the generics industry is already preparing for its ascension • Source: Shutterstock

Medicines for Europe has met with a high-level Ukrainian government delegation led by Maryna Slobodnichenko, the country’s deputy minister of health for European integration, putting forward ideas on how to plan the integration process of Ukraine into the EU.

Key takeaways:

  • The off-patent industry is making preparations for Ukraine’s eventual ascension into the EU

Kyiv applied for EU membership in February 2022 following the Russian invasion and was granted candidate status four months later

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival

 
• By Dean Rudge

Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.